Loading clinical trials...
Loading clinical trials...
Tyrosine kinase inhibitors (TKI) have greatly improved prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), with tumor responses in the majority of cases a...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Thoraxklinik-Heidelberg gGmbH
Collaborators
NCT04001777 · EGFR Positive Non-small Cell Lung Cancer
NCT04027647 · NSCLC Stage IIIB, NSCLC Stage IIIC, and more
NCT03126799 · EGFR Positive Non-small Cell Lung Cancer
NCT03402464 · EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
NCT01665417 · EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Thoraxklinik-Heidelberg gGmbH - Universitätsklinikum Heidelberg
Heidelberg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions